Practical aspects of prescribing a biologic

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 2, 2009, Pages

  Poulin, Yves ^a   Bourcier, Marc ^b,c  

^a LAVAL UNIVERSITY   (Canada)

^b Centre de Recherche Dermatologique du Quebec Metropolitain   (Canada)

^c Dermatology Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CREATININE; ETANERCEPT; INACTIVATED VACCINE; INFLIXIMAB; MERCAPTOPURINE; SUBUNIT VACCINE; TOXOID; USTEKINUMAB; VACCINE;

ANTHRAX; ARTICLE; BLOOD CELL COUNT; BODY SURFACE; CD4 LYMPHOCYTE COUNT; CHOLERA; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; DIPHTHERIA; DISEASE SEVERITY; DRUG HALF LIFE; EPIDEMIC ENCEPHALITIS; GLOMERULUS FILTRATION RATE; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LABORATORY TEST; LIVER FUNCTION TEST; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD; MENINGOCOCCEMIA; MULTIPLE SCLEROSIS; PERTUSSIS; PHYSICAL EXAMINATION; POLIOMYELITIS; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; RABIES; RISK FACTOR; SCREENING TEST; SEROLOGY; STREPTOCOCCUS PNEUMONIA; SYMPTOMATOLOGY; TETANUS; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TUBERCULOSIS; TYPHOID FEVER; VACCINATION; VIRUS INFECTION;

BIOLOGICAL FACTORS; DRUG PRESCRIPTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION DRUGS; PSORIASIS;

EID: 70449380958     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00026     Document Type: Article

References (17)

1. HUMIRA [product monograph]. St-Laurent (QC): Abbott Laboratories; 2008. Available at: http://www.abbott.ca/content/en_CA/20.10.210:210/product/ Product_Profile_0 210.htm (accessed December 10, 2008).
2. Amevive [product monograph]. Markham (ON): Astellas Pharma Canada; 2006. Available at: http://www.astellas.com/ca/en/derma_amevive_PM.html (accessed December 10, 2008).
3. Enbrel [product monograph]. Montreal: Wyeth Canada; 2008. Available at: http://www.wyeth.ca/en/products/ (accessed December 10, 2008).
4. Remicade [product monograph]. Kirkland (QC): Schering-Plough Canada; 2008. Available at: http://www.schering-plough.ca/English/our%20products/ products/default.asp?s=1#derma (accessed December 10, 2008).
5. Summary review: ustekinumab. Conshohocken (PA): Wolter Kluwers Health; 2008. Available at: www.formularymonographs.com/FMSRTF/ fandc-fms2273.rtf (accessed December 10, 2008).
6. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2004;8:321-37.
7. Lebwohl M, Bagel J, Gelfand JM, et al. From the medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94-105.
8. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
9. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
10. Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res 2006;20:757-90.
11. Finlay AY, Khan GK. Dermatology Quality of Life Index (DLQI). April 1992. Wales College of Medicine - Quality of Life - DLQI - Questionnaire. Available at: www.dermatology.org.uk (accessed December 9, 2008).
12. Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008;59:363-80.
13. Canada communicable disease report - Advisory Committee statement. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. CCDR-RMTC 2008;34(ACS/DCC-6):1-13. Available at: http://www.phac-aspc.gc.ca/publicat/ccdrrmtc/08vol34/acs-6/index-eng.php (accessed December 9, 2008).
14. Centers for Disease Control and Prevention. Update on adult immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1991;40(RR12):1-52. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00025228.htm (accessed December 10, 2008).
15. Public Health Agency of Canada. Canadian immunization guide 2006 Table 1. Type and contents of vaccines currently approved for use in Canada. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-tab01- eng.php (accessed December 9, 2008).
16. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9.
17. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645-60.